fig5

Figure 5. PgNVs treatment protects mice from AP-induced glucose intolerance. (A) Western blot of NQO1 and densitometry at 7 days after inducing AP, using vinculin as a loading control (n = 3); (B) OGTT indicated as the AUC, and plasma insulin levels in control, AP, and AP+PgNVs groups 7 days after inducing acute pancreatitis; (C) OGTT, showing the AUC and plasma insulin levels in control, AP and AP+PgNVs groups 30 days after acute pancreatitis; (D) Oral glucose test tolerance, showing the AUC and plasma insulin levels in control, AP, and AP + PgNVs groups 60 days after inducing acute pancreatitis; (E) Insulin detection showing representative images taken at 10× magnifications for each experimental group: control, AP, and AP + PgNVs at 7, 30 and 60 days. Scale bar: 10 µm. Measurements expressed as mean ± SD. *Significantly different from control group, P < 0.05; **significantly different from control group, P < 0.01; ^#significantly different from AP group, P < 0.05; ^##significantly different from AP, P < 0.01. AP: Acute pancreatitis; PgNVs: pomegranate-derived nanovesicles; NQO1: NAD(P)H quinone dehydrogenase 1; OGTT: oral glucose tolerance test; AUC: area under the curve; SD: standard deviation.